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a  b  s  t  r  a  c  t
The  simultaneous  quantitative  estimation  of tryptophan  (TRP)  and  its  metabolites  represents  a great
challenge  because  of  their  diverse  chemical  properties,  e.g.,  presence  of  acidic,  basic,  and  nonpolar
functional  groups  and  their  immensely  different  concentrations  in  biological  matrices.  A short  ultra
high-performance  liquid  chromatography  (UHPLC)–tandem  mass  spectrometry  (MS/MS)  method  was
validated  for  targeted  analysis  of TRP  and its 11  most  important  metabolites  derived  via  both  kynure-
nine  (KYN)  and  serotonin  (SERO)  pathways  in human  serum  and  cerebrospinal  fluid (CSF):  SERO,
KYN,  3-hydroxyanthranilic  acid,  5-hydroxyindoleacetic  acid, anthranilic  acid,  kynurenic  acid  (KYNA),  3-
hydroxykynurenine  (3-HK),  xanthurenic  acid,  melatonin,  picolinic  acid (PICA),  and  quinolinic  acid  (QUIN).
After selecting  the  “best”  reversed-phase  column  and  organic  modifier,  DryLab®4 was  used  to  optimize
the  gradient  time  and  temperature  in  chromatographic  separation.  To  achieve  absolute  quantification,
deuterium-labeled  internal  standards  were  used.  Among  all compounds,  3 were  analyzed  in  derivatized
(butyl  ester)  forms  (3-HK,  PICA,  and  QUIN)  and  the  remaining  9  in underivatized  forms.  Validation  was
performed  in  accordance  with  the  ICH  and  FDA  guidelines  to  determine  the  intraday  and  interday  preci-
sion,  accuracy,  sensitivity,  and  recovery.  To  demonstrate  the  applicability  of  the  developed  UHPLC–MS/MS
method,  the  aforementioned  metabolites  were  analyzed  in  serum  and  CSF  samples  from  patients  with
multiple  sclerosis  (multiple  sclerosis  group)  and  those  with  symptomatic  or  noninflammatory  neurolog-
ical diseases  (control  group).  The  concentration  of  QUIN dramatically  increased,  whereas  that  of  KYNA
slightly  decreased  in the  multiple  sclerosis  group,  resulting  in a significantly  increased  QUIN/KYNA  ratio
and  significantly  decreased  PICA/QUIN  ratio.
© 2020  Elsevier  B.V.  All  rights  reserved.
Abbreviations: 3-HANA, 3-hydroxyanthranilic acid; 3-HK, 3-
ydroxykynurenine; 5-HIAA, 5-hydroxyindoleacetic acid; aCSF, artificial
erebrospinal fluid; AGC, automatic gain control; ANA, anthranilic acid; CSF,
erebrospinal fluid; EDSS, expanded disability status scale; FA, formic acid; FD,
uorescence detector; GC, gas chromatography; HPLC, high-performance liquid
hromatography; HQC, high-level quality control; KAT, kynurenine aminotrans-
erase; KP, kynurenine pathway; KYN, l-kynurenine; KYNA, kynurenic acid; LOD,
imit of detection; LOQ, limit of quantification; LQC, low-level quality control; MELA,
elatonin; MQC, medium-level quality control; MS/MS, tandem mass spectrome-
ry; PFP, pentafluorophenyl; PICA, picolinic acid; PRM, parallel reaction monitoring;
C, quality control; QUIN, quinolinic acid; RPC, reversed-phase chromatography;
RMS, relapsing-remitting multiple sclerosis; RSD, relative standard deviation;
ERO, serotonin; SIL-IS, stable isotope-labeled internal standard; TRP, tryptophan;
HPLC, ultra high-performance liquid chromatography; XA, xanthurenic acid.
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The kynurenine (KYN) pathway (KP) is the major metabolic
pathway of the essential amino acid tryptophan (TRP), which
leads to the production of neuroprotective and neurotoxic com-
pounds. Changes in the concentrations of neuroprotectants such
as kynurenic acid (KYNA) and picolinic acid (PICA) have been
described in different diseases, but the excitotoxin quinolinic acid
(QUIN) and the free radical generator 3-hydroxykynurenine (3-HK)
are associated with different neurodegenerative diseases including
multiple sclerosis [1]. KYNA is an endogenous glutamate receptor
antagonist that affects all ionotropic glutamate receptors including
NMDA, kainate, and AMPA receptors, and it exhibits the high-
est affinity for the NMDA receptor and displays antioxidant and
free radical-scavenging activities [2]. Conversely, QUIN is known
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or its broad-spectrum neurotoxic effects including its role as an
MDA receptor agonist, in addition to its roles in antioxidant
epletion, lipid peroxidation, and oxygen intermediate generation
1].
Multiple sclerosis is a disabling autoimmune, inflammatory,
eurodegenerative, demyelinating disease affecting the central
ervous system. The diagnosis of multiple sclerosis is based on clin-
cal symptoms suggestive of demyelinating disorders as proven by
RI  and lumbar puncture. In addition to dissemination of the dis-
ase in space and time, it is essential to exclude other diseases.
ccording to McDonald’s criteria, as revised in 2017, oligoclonal
ammopathy in cerebrospinal fluid (CSF) or the simultaneous pres-
nce of gadolinium-enhancing and nonenhancing lesions can verify
issemination in time. Dissemination in space can be proven by
he presence of one or more T2 lesions in the periventricular, corti-
al, juxtacortical, or infratentorial space or spinal cord [3]. Multiple
clerosis is considered active if the following findings are present:
elapse, confirmed expanded disability status scale (EDSS) progres-
ion, new/enlarged MRI  lesions, and disease-related brain atrophy
4].
Recently, multiple sclerosis subtypes were differentiated
ccording the concentrations of the different TRP metabo-
ites [1,5] because changes in their concentrations appear to
erve as potential biomarkers. For example, in acute relapse of
elapsing–remitting multiple sclerosis (RRMS), increased neuro-
oxic QUIN concentration, higher QUIN/KYN and QUIN/KYNA ratios
6], and lower KYNA concentration can be observed in CSF, whereas
ncreased KYNA concentration were found in plasma. The expres-
ion of KYN aminotransferase (KAT) also increased in red blood
ells. Decreased TRP concentration in both serum and CSF were
escribed in patients with RRMS compared with those in control
ubjects. Interestingly, during remission, lower KYNA concentra-
ion can be observed in CSF [7], whereas higher KYNA concentration
an be found in patients with the progressive form of multiple
clerosis [8].
The simultaneous quantitative estimation of TRP and its
etabolites represents a great challenge because of their diverse
hemical properties, namely, presence of acidic, basic, and nonpo-
ar functional groups and their immensely different concentrations
n biological matrices such as serum (plasma) and CSF. Numerous
hromatographic methods have been developed for the successful
uantitative estimation of these metabolites using gas chromatog-
aphy (GC), high-performance liquid chromatography (HPLC), ultra
igh-performance liquid chromatography (UHPLC) coupled with
 fluorescence detector (FD), a UV detector, or tandem mass
pectrometry (MS/MS) [8–11]. The advantages of UHPLC–MS/MS
nclude its sensitivity, ability to quantitate multiple compounds in
 single run, short elution time, excellent separation efficiency, and
equirement of small sample amount. Hényková et al. [9] developed
 UHPLC–MS/MS method for the quantitative estimation of TRP,
YN, 3-HK, KYNA, 3-hydroxyanthranilic acid (3-HANA), anthranilic
cid (ANA), serotonin (SERO), melatonin (MELA), and other impor-
ant neuroactive metabolites derived from TRP in human CSF and
erum. Fuertig et al. [10] described the successful quantitative esti-
ation of 13 compounds related to TRP in the brains and plasma of
ice and CSF and plasma of nonhuman primates. However, none
f these studies considered the separation and peak shape of early
luting components. Because of the different chemical characteris-
ics of TRP and its metabolites, the combination of several methods
as used to measure their concentrations by Guillemin et al. [8]
ncluding UHPLC coupled with a diode array detector and an FD
ere used to measure TRP, KYN, 3-HK, 3-HANA, and ANA concen-rations using isocratic separation. In addition, gradient elution was
erformed to measure KYNA concentration using an FD, and GC
oupled with a mass spectrometer was used to measure PICA and
UIN concentrations.ceutical and Biomedical Analysis 185 (2020) 113246
The main purpose of the current study was to develop a new,
robust UHPLC–MS/MS method to quantify the concentrations
of TRP and its 11 most important metabolites (Fig. 1), which
were derived via both KP and SERO pathways, including the
concentrations of the rarely measured metabolites PICA and QUIN.
Optimization of a chromatographic method can be supported
and accelerated using in silico simulation software [12] to define
the most appropriate conditions for rapid, sensitive, precise, and
reproducible analysis as economically as possible. After column
and organic modifier scouting, the DryLab®4 method develop-
ment/optimization software [13] was  applied to predict retention
and resolution as functions of gradient time (tG) and temperature
(T).
To the best of our knowledge, this is the first report on the simul-
taneous quantitative characterization of endogenous SERO, KYN,
3-HANA, TRP, 5-hydroxyindoleacetic acid (5-HIAA), ANA, KYNA, 3-
HK, xanthurenic acid (XA), MELA, PICA, and QUIN in serum and CSF
of patients with multiple sclerosis using UHPLC–MS/MS.
2. Materials and methods
2.1. Reagents and chemicals
All reagents and chemicals were of analytical or LC–MS grade.
TRP and its metabolites d4-PICA and n-butanol were purchased
from Sigma-Aldrich (St. Louis, MO,  USA). d3-3-HK was obtained
from Buchem B. V. (Apeldoorn, The Netherlands). Other deuterated
internal standards (ISs; d4-SERO, d4-KYN, d3-3-HANA, d5-TRP,
d5-5-HIAA, d5-KYNA, d4-XA, d4-MELA, and d3-QUIN) were pur-
chased from Toronto Research Chemicals (Toronto, ON, Canada).
Acetonitrile (ACN), methanol (MeOH), water, HPLC-grade ammo-
nium formate, and ammonium acetate were obtained from VWR
Chemicals (Monroeville, PA, USA). Formic acid (FA) was  purchased
from Fisher Scientific (Portsmouth, NH, USA) and acetyl chloride
from Alfa Aesar (Haverhill, MA,  USA).
2.2. Preparation of standard, IS, and quality control (QC) solutions
Stock solutions were prepared individually at a final concentra-
tion of 1 mg/mL, except 3-HK and d3-3-HK (0.5 mg/mL). According
to their stability and solubility, several solvents were used. SERO,
d4-SERO, TRP, d5-TRP, ANA, PICA, and d4-PICA were dissolved in
water–MeOH–FA–ascorbic acid (50:50:0.1:0.02, v/v/v/v). KYN, d4-
KYN, 5-HIAA, d5-5-HIAA, 3-HK, d3-3-HK, MELA, d4-MELA, QUIN,
and d3-QUIN were dissolved in MeOH containing 0.1 % (v/v) FA and
0.02 % (v/v) ascorbic acid. 3-HANA, d3-3-HANA, KYNA, d5-KYNA,
XA, and d4-XA were dissolved in dimethyl sulfoxide. All standard
stock solutions were prepared on ice, divided into 200-L aliquots,
and stored at −80 ◦C until further use.
Calibration standards were prepared at 12 levels and QC
samples at three levels (low-level QC [LQC], eighth point of
calibration; middle-level QC [MQC], fourth point of calibration;
and high-level QC [HQC], second point of calibration) in arti-
ficial CSF (aCSF; containing 127 mM NaCl, 1.0 mM KCl, 1.2 mM
KH2PO4, 26 mM NaHCO3, 10 mM  d-glucose, 2.4 mM CaCl2, 1.3 mM
MgCl2, and 5.26 M bovine serum albumin) [14] for CSF analy-
sis. Calibration standards comprised 250 L aCSF, 20 L standard
solution mix  (31.25–1000 nM SERO, 6.25–200 nM KYN, 0.25–8 nM
3-HANA, 250–8000 nM TRP, 12.5–400 nM 5-HIAA, 0.6–20 nM ANA,
0.25–8 nM KYNA, 1.25–40 nM 3-HK, 0.1–2 nM XA, 0.25–8 nM MELA,
2–60 nM PICA, and 5–160 nM QUIN in 0.1 % [v/v] aqueous FA),
and 910 L ice-cold ACN containing 10 L stable isotope-labeled
(SIL)-IS mix  (800 nM d4-SERO, 20 nM d4-KYN, 3 nM d3-3-HANA,
4000 nM d5-TRP, 200 nM d5-5-HIAA, 2 nM d5-KYNA, 8 nM d3-
3-HK, 0.4 nM d4-XA, 4 nM d4-MELA, 15 nM d4-PICA, and 25 nM
d3-QUIN).
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Table 1
Detailed demographic and clinical data of the study population.
Subject Multiple sclerosis group Control group
Age in years (mean ± SD) 33.84 ± 9.14 37.57 ± 10.09
Age at onset (mean ± SD) 32.47 ± 9.00 –
EDSS (median, IQR) 0.5 (0, 1.5) –ig. 1. Simplified pathways of tryptophan metabolism, indicating the principl
ryptophan-2,3-dioxygenase (TDO), kynureninase (KYNU), and kynurenine-3-mono
The calibration standards and QC samples for serum anal-
sis were prepared in charcoal-stripped human serum, which
as prepared as described by Möller et al. [15]. Briefly, 1.2 g of
harcoal-activated powder (Fisher Scientific) was  added to 20 mL
erum, rotated for 2 h, and centrifuged at 14,000 ×g for 10 min
o obtain the supernatant. Then, “blank” serum was confirmed by
C–MS/MS to be free of TRP and its metabolites. Calibration stan-
ards comprised 100 L “blank” serum, 10 L standard solution
ix  [156.25–5000 nM SERO, 312.5–10000 nM KYN, 7.8–250 nM 3-
ANA, 6.25–200 M TRP, 7.8–250 nM 5-HIAA, 6.25–200 nM ANA,
.7–150 nM KYNA, 6.25–200 nM 3-HK, 1.5–50 nM XA, 0.16–5 nM
ELA, 3.125–100 nM PICA, and 62.5–2000 nM QUIN in 0.1 % (v/v)
queous FA], and 370 L ice-cold acetone:MeOH (1:1, v/v) contain-
ng 10 L SIL-IS mix  (1500 nM d4-SERO, 1000 nM d4-KYN, 65 nM
3-3-HANA, 5250 nM d5-TRP, 200 nM d5-5-HIAA, 50 nM d5-KYNA,
0 nM d3-3-HK, 25 nM d4-XA, 4 nM d4-MELA, 80 nM d4-PICA, and
00 nM d3-QUIN). Concentrations were selected in accordance
ith endogenous analyte concentrations and to reach a proper
ignal to noise ratio.
.3. Collection of human CSF and serum samples
The females included in this study, who underwent both lumbar
uncture and blood sample collection, were enrolled at the Depart-
ent of Neurology, University of Szeged. Approval for the human
tudy was granted by the local Ethical Committee of the Univer-
ity of Szeged (46/2014 and 143/2015), and the study protocol
dhered to the tenets of the most recent revision of the Decla-Data are presented as the mean ± SD or median and interquartile range for EDSS.
EDSS, expanded disability status scale; IQR, interquartile range; SD, standard devi-
ation.
ration of Helsinki for experiments involving humans. All enrolled
subjects provided voluntary signed informed consent for participa-
tion. Inclusion criteria for the multiple sclerosis group were older
than 18 years, female sex, diagnosis of RRMS, clinical follow-up
for at least 2 years, and availability of serum and CSF samples at
the biobank at the time of diagnostic lumbar puncture (n = 20). The
demographic and clinical data of the cohort are presented in Table 1.
Disability was  quantitatively estimated using EDSS. EDSS values
ranged between 0 and 5.5 (median = 0.5). Age-matched patients
(n = 14) with symptomatic neurological disorder (e.g., headache)
or noninflammatory neurological disease (e.g., benign intracranial
hypertension) who  had been followed up for at least 2 years served
as the control group.
CSF samples were centrifuged immediately after lumbar punc-
ture at 3500 rpm for 10 min, and aliquots of 500 L were stored
at −80 ◦C until further use. Whole-blood samples were collected
in Vacutainer tubes, centrifuged, and the supernatant stored as
mentioned previously. Serum and CSF samples were collected and
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ig. 2. Flow chart of the sample preparation process of human CSF and serum samp
SF,  cerebrospinal fluid; FA, formic acid; ACN-SIL-IS, acetonitrile containing sta
erformance liquid chromatography-tandem mass spectrometry.
tored according to the standardized international biobanking con-
ensus protocol of the BIOMS-Eu network [16].
.4. Preparation of human CSF and serum samples for analysis
Prior to profiling the KP and SERO pathways, samples were rela-
eled; therefore, a blind study was conducted. To 250 L of each
SF sample, 20 L 0.1 % (v/v) of aqueous FA and 910 L ice-cold
CN containing 10 L SIL-IS mix  (the same as used in the prepa-
ation of the calibration standards) were added, and the mixture
as vortexed for 30 s. It was allowed to rest for 15 min  at −20 ◦C,
ortexed for 60 s to support protein precipitation, and incubated
or another 15 min  at −20 ◦C. The supernatant was obtained via
entrifugation of the mixture for 15 min  at 12,000 ×g at 4 ◦C. The
upernatant (1120 L) was transferred to a new tube, centrifuged
or 15 s, and split into two equal parts. After concentration under
acuum (Savant SC 110 A Speed Vac Plus, Savant, USA), half of the
ample was treated with 70 L derivatizing reagent (n-butanol-
cetyl chloride, 9:1, v/v) and incubated for 1 h at 60 ◦C. The mixture
as dried under nitrogen before reconstitution. Both parts of the
ample were dissolved in 100 L starting eluent, vortexed, cen-
rifuged, and combined (Fig. 2).
Serum samples were prepared in the same manner, except that
o 100 L of serum sample were mixed with 10 L 0.1 % (v/v) aque-
us FA and 370 L ice-cold acetone–MeOH (1:1, v/v) containing
0 L SIL-IS mix, and 400 L supernatant was processed further
Fig. 2).
.5. Instrumentation and UHPLC–MS/MS analysis.5.1. Development and optimization of UHPLC separation
UHPLC separation of TRP and its metabolites was performed
n an ACQUITY I-Class UPLCTM liquid chromatography system
Waters, Manchester, UK) comprising Binary Solvent Manager,tope-labeled internal standard; n-BuOH, n-butanol; UHPLC–MS/MS, ultra high-
Sample Manager-FL, and Column Manager. The dwell volume of
the system was  100 L.
To select the most appropriate column for analyte separa-
tion, the following reversed-phase columns were tested: BEH C18
2.1 × 50 mm  (1.7 m)  and Cortecs C18 2.1 × 50 mm (1.6 m)  from
Waters (Milford, MA,  USA) and Kinetex C18 2.1 × 100 mm (2.6 m);
Kinetex EVO C18 2.1 × 150 mm (5.0 m);  Luna C18 2.0 × 100 mm
(2.5 m);  Luna Omega Polar C18 2.1 × 50 mm,  (1.6 m);  Luna
Omega PS C18 2.1 × 50 mm (1.6 m),  Kinetex C8 2.1 × 150 mm
(2.6 m),  Jupiter Proteo C12 2.0 × 150 mm (4.0 m), and Luna
Phenyl-Hexyl 2.1 × 100 mm (2.6 m)  from Phenomenex (Torrance,
CA, US).
Chromatograms were developed with a generic MS-compatible
gradient from 2 % to 80 % B in 7 min  using 0.1 % FA as solvent A
and 0.1 % FA in MeOH as solvent B. Similar gradient elution was
performed using ACN in solvent B as an organic modifier. For each
measurement, the flow rate was  set at 300 L/min and T at 25 ◦C.
In total, 20 L of a standard mixture containing 2 g/mL of each
analyte was injected into the columns. The UHPLC system was
controlled using MassLynx 4.1 SCN 901 (Waters).
To optimize separation on the “best” column, a 2D retention
model was  built on the basis of four chromatographic runs after
injection of a mixture of all analytes. The tG values were set at
5 and 15 min  to linearly change the eluent composition from 10
% to 90 % MeOH containing 0.1 % FA. Chromatography was per-
formed at 25 ◦C and 50 ◦C at a flow rate of 300 L/min. Peaks in
different chromatograms were identified by detecting the molec-
ular ions of every analyte on a mass spectrometer. The resulting
chromatographic data (retention time, peak width, and area) were
entered into DryLab®4 (Molnár-Institute, Berlin, Germany) to cre-
ate a 2D resolution map  displaying the critical resolutions of the
peaks separated against tG and T.
Chromatographic separation for quantitative estimation of TRP
and its 11 metabolites in CSF and serum was performed at
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5 ◦C on a pentafluorophenyl (PFP) column (Phenomenex; 100 Å,
00 mm × 2.1 mm,  particle size 2.6 m;  “best” column) protected
y a PFP guard column (Phenomenex) using 0.1 % (v/v) aqueous FA
s solvent A and MeOH containing 0.1 % (v/v) FA as solvent B. The
nal gradient was set as follows: 0.0 min, 10 % B; 1.0 min, 30 % B;
.0 min, 50 % B; 3.5 min, 90 % B; 5.0 min, 90 % B; 5.1 min, 10 % B;
nd 7 min  10 % B. For each measurement, the flow rate was set at
00 L/min. Sample T was maintained at 5 ◦C. Finally, 20 L of the
ample was injected into the UHPLC–MS/MS system.
.5.2. Optimization of mass spectrometric analysis
All mass spectrometric measurements were conducted using
he Q ExactiveTM Plus Hybrid Quadrupole-Orbitrap Mass Spectrom-
ter (Thermo Fisher Scientific, San Jose, CA, USA) connected online
o the UHPLC instrument. The instrument was  operated in the
ositive-ion mode using the equipped HESI-II source with the fol-
owing parameters: capillary T, 256 ◦C; spray voltage, 3.5 kV; aux
as heater T, 406 ◦C; sheath gas flow, 48; aux gas flow, 11; sweep
as flow, 2; and S-lens RF level, 50.0 (source auto-defaults). Full scan
as conducted with a mass range of 50–300 m/z and resolution of
7,500. The automatic gain control (AGC) setting was defined as
 × 106 charges, and the maximum injection time was set to 60 ms.
For quantitative mass spectrometric analysis of TRP and its
etabolites using MS/MS, the parallel reaction monitoring (PRM)
ata acquisition mode was selected. To reach the best precur-
or/product transition for quantitation and maximize sensitivity,
he optimal fragmentation conditions and collision energies of
ach analyte were identified. This optimization procedure was
erformed for each individual standard by directly infusing each
olution into the ion source using a Hamilton syringe at a flow rate
f 20 L/min.
The concentrations of TRP and its metabolites in biological sam-
les were measured by monitoring the appropriate transitions
Table 2) determined previously. AGC target was set at 5 × 106
harges for TRP and d5-TRP because of their higher concentra-
ions and 2 × 105 charges for the remaining analytes. The maximum
njection time was set at 60 ms  and resolution at 17,500. A divert
alve placed after the analytical column was programmed to switch
ow onto the mass spectrometer only when analytes of interest
luted from the column (1.4–5.0 min) to prevent excessive contam-
nation of the ion source and ion optics. The washing procedures
f the autosampler before and after injecting samples were pro-
rammed to avoid carryover of analytes.
Control of the mass spectrometer, data acquisition, and data
rocessing was conducted using XcaliburTM 4.1 (Thermo Fisher
cientific).
.6. Method validation
Biological matrices devoid of TRP and its metabolites are not
eadily available; hence, surrogate matrices (aCSF and “blank”
erum) were used to demonstrate the efficiency of the method. In
his study, SIL-IS analogs were used to validate the UHPLC–MS/MS
ethod. For validation, the linearity, limits of detection (LOD)
nd quantification (LOQ), precision, accuracy, and recovery were
ssessed following the ICH and FDA guidelines [17,18].
.6.1. Linearity, LOD, and LOQ
The calibration curves of the 12 analytes were constructed from
he peak area ratios of the compound to SIL-IS at 11 levels using
ixed working standard solutions. According to the acceptance cri-eria, the calibration curve should have a correlation coefficient (r2)
f 0.99 or better. The LOD and LOQ of each analyte were calculated
ased on the standard error of the intercept. LOD and LOQ were cal-
ulated using the formulas 3.3 ×  / S and 10 ×  / S, respectively,ceutical and Biomedical Analysis 185 (2020) 113246 5
where  is the standard error of the y-intercept and S is the slope
of the calibration curve (Supplementary Tables 1–2).
2.6.2. Precision and accuracy
The accuracy and intraday and interday precisions were calcu-
lated by determining five replicates of LQC, MQC, and HQC samples
over 3 consecutive days (n = 45). The concentration values of QCs
are presented in Supplementary Tables 3–6.
Regarding precision, the acceptance criterion was ±15 % with
respect to relative standard deviation (RSD). Regarding accuracy,
the limit was the same relative to definite concentrations.
2.6.3. Recovery
To determine recovery, two  batches were prepared as described
previously [19]. The first batch was spiked before protein pre-
cipitation, whereas the second batch was  spiked after protein
precipitation. To achieve reliable results, five LQC, MQC, and HQC
replicates were prepared (see Chapter 2.2). The recovery of TRP and
its metabolites was estimated by comparing the calculated concen-
tration ratios of the two  batches at three QC levels (LQC, MQC, and
HQC; n = 45).
2.7. Statistical analysis
The calculation of peak area ratios and the calibration and
quantitation of analytes were performed from collected raw data
using XcaliburTM Quan Browser (Thermo Fisher Scientific). The pro-
cessed data including peak area, peak area ratio, retention time,
and concentration were exported into Microsoft Excel to create an
appropriate file for input in the R software [20]. The normality of
the variables was  checked using the Kolmogorov–Smirnov test and
visually checked using quantile–quantile plots, and the equality of
variances was examined using Welch’s F-test. Outliers were iden-
tified using Grubbs’s test. To compare data between the control
and multiple sclerosis groups, box plots with SDs were generated.
Comparisons between the two groups were conducted using an
independent samples t-test or two-sample Wilcoxon test in R. A
p-value of <0.05 was  considered statistically significant.
3. Results and discussion
3.1. Optimization of sample preparation
The analysis of small molecules using LC–MS usually requires
cleanup procedures to eliminate the worst interfering compounds
and to concentrate the sample if the analyte is present at
extremely low concentrations. Biological samples contain proteins
that adversely affect the analysis of small molecules. To improve
sensitivity, proteins in samples had to be eliminated. In our pre-
liminary experiments, four different precipitation solvents were
compared with their 3× and 5× volumes in human serum samples
[i.e., MeOH, ACN, acetone–MeOH (3:7, v/v), and acetone–MeOH
(1:1, v/v)] and two  different solvents in CSF samples (i.e., MeOH
and ACN) to monitor the recovery of each TRP metabolite. 3-HANA
could not be detected using MeOH (data not shown). The best result
was achieved using 3× volume of ACN to precipitate the majority
of proteins in CSF samples and 3× volume of acetone–MeOH (1:1,
v/v) for serum samples (see Chapter 3.3.3).
In a complex quantitative bioanalytical method, the use of SIL-IS
can help control the variability of the method. Because it is pro-
cessed along with the analyte, SIL-IS should both help correct for
variability in sample preparation during extraction and chemical
derivatization and compensate for variability in MS  detection. In
the present study, 11 deuterated equivalents of TRP metabolites
were added at the beginning of analysis to control every step of
the analytical procedure. Unfortunately, the deuterated form of
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Table 2
Exact mass of the precursor, quantifier, and qualifier ions and the optimal collision energies of the analytes in the PRM method; their experimental (texp) and simulated (tsim)
retention times, and their ratio (texp/tsim) in optimized ultra high-performance liquid chromatographic separation.
Analyte Precursor ion [M+H]+ Quantifier ion [M+H]+ Qualifier ion [M+H]+ CE (eV) texp (min) tsim (min) texp/tsim
SERO 177.1022 115.0548 132.0810 32 1.53 1.50 1.02
d4-SERO 181.1273 119.0704 136.1060 32 1.53 1.50 1.02
KYN  209.0919 94.0660 146.0603 14 1.61 1.59 1.01
d4-KYN  213.1169 98.0912 150.0856 14 1.61 1.59 1.01
3-HANA 154.0499 136.0393 108.0453 10 2.26 2.24 1.01
d3-3-HANA 157.0688 139.0582 111.0812 10 2.26 2.24 1.01
TRP  205.0973 118.0652 188.0706 18 2.42 2.38 1.01
d5-TRP  210.1285 123.0968 193.1018 18 2.42 2.38 1.01
5-HIAA  192.0659 146.0600 117.0570 18 2.69 2.65 1.01
d5-5-HIAA 197.0972 150.0852 122.0685 18 2.69 2.65 1.01
ANA  138.0547 92.0503 120.0449 20 3.06 3.03 1.01
KYNA  190.0502 116.0503 162.0552 38 3.54 3.55 1.00
d5-KYNA 195.0806 121.0816 167.0867 38 3.54 3.55 1.00
XA  206.0450 178.0508 132.0443 21 3.90 3.91 1.00
d4-XA  210.0695 182.0761 136.0691 21 3.90 3.91 1.00
3-HK  281.1496 152.0709 110.0606 15 3.99 4.03 0.99
d3-3-HK 284.1684 155.0897 113.1082 15 3.99 4.03 0.99
MELA  233.1284 130.0654 115.0546 54 4.11 4.16 0.99
d4-MELA 237.1536 134.0907 119.0801 54 4.11 4.16 0.99
PICA  180.1019 96.0453 124.0396 28 4.38 4.43 0.99
d4-PICA 184.1270 100.0702 128.0647 28 4.38 4.43 0.99
QUIN  280.1543 96.0453 124.0396 37 4.63 4.61 1.00
d3-QUIN 283.1732 99.0641 128.0647 37 4.63 4.61 1.00
CE, collision energy; SERO, serotonin; KYN, l-kynurenine; 3-HANA, 3-hydroxyanthranilic acid; TRP, tryptophan; 5-HIAA, 5-hydroxyindoleacetic acid; ANA, anthranilic acid;
KYNA,  kynurenic acid; XA, xanthurenic acid; 3-HK, 3-hydroxykynurenine; MELA, melatonin; PICA, picolinic acid; QUIN, quinolinic acid.
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NA was unavailable; therefore, for its quantitative estimation,
5-KYNA, which has a similar chromatographic elution time, was
sed.
Some TRP metabolites (3-HK, PICA, and QUIN) have unfavor-
ble chromatographic properties, making their quantitative LC–MS
stimation unreliable. The chromatographic properties of analytes
an be modified via derivatization. Changes in the structure of an
nalyte usually affect its physical and chemical properties (e.g.,
olarity, solubility, stability, and ionization efficiency in mass spec-
rometry), which can alter the separation characteristics of the
nalyte (e.g., improved peak shape, elution time, peak symmetry,
fficiency, and plate count) [21]. If these changes are favorable,
hey might lead to improvement in the separation of the analyte.
egarding precolumn derivatization, the selected reaction must be
uantitative or, at least, reproducible and free of byproducts.
At the same time, chemical modification may  serve to minimize
atrix interference by moving the compound to a position on thehromatogram where interference with the matrix component is
inimal.
Except SERO and MELA, TRP and its metabolites have carboxyl
roup(s). The most frequently used approach for derivatizing car-t) forms of 3-hydroxykynurenine (3-HK, green peaks), picolinic acid (PICA, orange
boxylic acids is esterification with a short-chain aliphatic alcohol in
the presence of an acid as a catalyst [22]. Although this established
esterification method (Fischer esterification) leads to equilibrium,
the reaction can be shifted toward the products by applying excess
amount of alcohol. Esterification of TRP and its metabolites was
performed using MeOH, ethanol, n-propanol, or n-butanol. Because
they have the longest hydrophobic aliphatic chains, the butylated
products exhibited the highest retention when reversed-phase
columns were used, and there was  no coelution of the esterified
and nonderivatized components (data not shown). Butyl ester for-
mation changed the polarity of the molecules, resulting in the
formation of well-retained peaks with excellent peak shapes in
cases of 3-HK, PICA, and QUIN (Fig. 3). Esterification of analytes
with the mixture of n-butanol and acetyl chloride is a commonly
used procedure to derivatize amino acids for newborn amino acid
screening via mass spectrometry [22].
The derivatization method was  optimized by assessing the effect
of reaction time (0, 20, 30, 40, 50, and 60 min; n = 3; Fig. 4), and the
maximum conversion of carboxyl group(s) to esters was  achieved
after 60-min reaction. Although esterification was  not complete
after 60 min  for all components (74 %–95 %), the method could be
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Table  3
Physicochemical properties (hydrogen bond donor/acceptor groups, pKa, logP, logD, and isoelectric point) of tryptophan metabolites (calculated using ChemAxon’s Chemi-
calize  software [24]).
Analyte Molecular mass (g/mol) pKa1 pKa2 pKa3 pI logP logD (pH3) logD (pH6) logD (pH9) Hydrogen bond
donor count
Hydrogen bond
acceptor count
SERO 212.68 9.31 10.00 9.78 0.48 −1.85 −1.76 0.32 3 2
KYN  306.29 1.19 8.96 6.11 −1.91 −2.35 −1.91 −2.20 3 5
3-HANA 153.14 1.94 10.37 4.82 3.03 1.15 0.75 −0.42 −2.36 3 4
TRP  204.23 2.54 9.40 5.97 −1.09 −1.19 −1.09 −1.22 3 3
5-HIAA 191.18 4.22 9.56 – 1.41 3.80 −0.38 −2.16 3 3
ANA  137.14 4.89 1.95 3.34 1.45 1.27 0.17 −2.00 2 3
KYNA  189.17 2.47 2.31 1.87 2.40 −0.47 −1.68 2 4
XA  205.17 2.17 9.06 14.22 3.25 −0.17 −0.17 −0.65 −2.22 3 5
3-HK  224.21 0.99 9.86 3.37 8.90 6.11 −2.21 −2.73 −2.21 −2.57 4 6
MELA  232.28 −1.57 15.90 7.08 1.15 1.15 1.15 1.15 2 2
PICA  123.11 1.00 5.52 3.04 −0.65 −0.65 −1.25 −2.71 1 3
QUIN  167.12 0.31 4.16 6.67 2.27 −1.2 −1.23 −3.11 −6.39 2 5
SERO, serotonin; KYN, l-kynurenine; 3-HANA, 3-hydroxyanthranilic acid; TRP, tryptophan
XA,  xanthurenic acid; 3-HK, 3-hydroxykynurenine; MELA, melatonin; PICA, picolinic acid
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inic acid, red; 3-hydroxykynurenine, green; picolinic acid, orange.
eliably used because of the presence of SIL-IS, which has nearly
dentical chemical and physical properties as the target analyte.
lthough the absolute response may  be affected, the analyte/IS
eak area ratio should be unaffected and the method should be
ccurate, precise, and rugged.
During sample preparation, all carboxyl group-containing com-
ounds were esterified in 50 % of the samples and remixed with
he untreated fraction to analyze butylated 3-HK, PICA, and QUIN
n the same chromatographic run with SERO, MELA, and the
on-esterified carboxyl group-containing TRP and its remaining
etabolites.
.2. Development and optimization of the UHPLC method
LC–MS is one of the most prominent analytical techniques
ecause of its inherent selectivity and sensitivity. Most currently
sed HPLC/UHPLC separation techniques are performed using
eversed-phase chromatography (RPC). RPC has become the stan-
ard technique for analyzing a wide range of small (even large)
ompounds ranging from neutral polar and nonpolar solutes to
cidic, basic, and amphoteric compounds. Stationary phases used
n RPC typically comprise varying lengths of hydrocarbons such
s C18, C8, and C4, for which analyte retention is mainly driven by
ydrophobic and van der Waals interactions. As the mobile phase, a
ixture of water with a miscible, polar organic solvent such as ACN
nd MeOH is used, usually supplemented with different additives.
TRP and some of its metabolites are rather hydrophobic because
f the indole or phenyl ring; however, the attached pyridine ring
nd hydroxy, amine, or carboxy groups increase their hydrophilic-
ty while providing ionic properties to molecules. Developing an; 5-HIAA, 5-hydroxyindoleacetic acid; ANA, anthranilic acid; KYNA, kynurenic acid;
; QUIN, quinolinic acid.
LC MS  method for the simultaneous quantitative estimation of
these types of target compounds is extremely challenging because
of the great diversity in their physicochemical properties (e.g.,
pKa, isoelectric point, hydrophobicity, number of hydrogen bond
donor/acceptor groups, and solubility; Table 3).
The first stage of chromatographic method development is iden-
tifying the most promising column chemistry, organic modifier, and
pH of the mobile phase for analyte separation. To scout the most
appropriate column and organic solvent, we performed two  ini-
tial experiments using a number of columns with elution using a
MS-compatible generic gradient (see Section 2.5.1). The “best” col-
umn  and organic modifier were selected via visual comparison of
the resultant chromatograms, taking into account the overall peak
shapes, retention of highly polar compounds, and baseline separa-
tion of analytes in the shortest time. Then, DryLab®4 was used to
optimize separation on the selected column.
An octadecylsilane column is the first choice for separating TRP
and its metabolites; therefore, we  tested seven C18 columns. Sep-
aration was  also performed on reversed-phase columns containing
other hydrocarbon groups (C8, C12, and phenyl-hexyl). Because
of the different characteristics of the tested stationary phases,
they exhibited distinct retention and elution profiles. PICA was  the
first eluting analyte on all columns, but satisfactory retention was
observed only using the BEH C18 and Luna Omega Polar columns.
The early eluting QUIN could not be detected using the Kinetex C18
and Cortecs C18 columns, whereas it appeared as a wide peak when
the BEH C18 and Luna C18 columns were used. Its elution profile
was unacceptably wide on the other columns. 3-HK exhibited low
retention, and it sometimes eluted as double peaks (Luna C18, BEH
C18, Polar C18, and Cortecs C18 columns). The peak of SERO had
fronting and tailing on the Kinetex C18, Luna C18, BEH C18, and
Cortecs C18 columns. The peak shape of XA was unacceptable on
the Luna C18, Kinetex C18, Cortecs C18, and phenyl-hexyl columns.
TRP, 5-HIAA, ANA, KYNA, and XA grouped at the second part of chro-
matograms in 0.6–1.3-min windows usually as unseparated peaks.
Stationary phases with shorter alkyl chains proved to be even less
retentive for these analytes; therefore, we  had to search for other
types of reversed-phase columns.
Retention times were shorter and peaks were somewhat sharper
using ACN as an organic modifier; however, no important selectiv-
ity or sensitivity differences were observed.
Fluorinated stationary phases, particularly those involving PFP
moieties, have become popular alternatives to the traditional alkyl
phases because of the differences in selectivity and retention that
they provide. PFP phases use multiple retention mechanisms to
separate small, highly polar aromatic compounds [23], and they
appear to be ideal choices for analyzing TRP metabolites. The elec-
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ronegative fluorine atoms produce an electron-deficient phenyl
ing, which permits the PFP phase to act as a Lewis acid or an
lectron acceptor. – interactions can occur with solutes rich
n electrons (Lewis bases) such as amino and hydroxyl groups.
arbon–fluorine bonds are extremely polar, thus enabling analytes
o also be retained by dipole–dipole interactions, H-bonding, and
ometimes ionic interactions, resulting in increased analyte reten-
ion. In the presence of a rigid aromatic ring, the solute shape can
lso dictate selectivity. The predominance of each retention mecha-
ism is influenced by the physicochemical properties and structure
f analytes and the chromatographic conditions used.
Core-shell Kinetex F5 (2.1 × 150 mm,  2.6 m) and two Kinetex
FP (2.1 × 100 mm,  2.6 m;  Phenomenex) columns with different
ot numbers were tested using the abovementioned generic gra-
ients. Similarly, as observed for the C18 stationary phases, PICA,
UIN, and 3-HK eluted in wide, skewed peaks from every fluori-
ated phase. Despite the different structures (distinct functional
roups on benzene, pyridine, or indole rings), the pKa values and
-bonding capabilities of KYN–SERO and 5-HIAA–KYNA–XA pairs
ould not be resolved on the Kinetex F5 column, as observed for
-HANA–KYN and XA–TRP pairs on the Kinetex PFP column (from
ewer series). The older Kinetex PFP column could separate the
bovementioned analyte pairs using MeOH as an organic modifier,
nd it generally produced a “good-looking” chromatogram (except
ICA, QUIN, and 3-HK). Choosing ACN instead of MeOH resulted in
ifferences in selectivity; however, 3-HANA and TRP were coeluted,
ollowed by deteriorated quantification of 3-HANA because the
oncentration of TRP in serum and CSF are at least three orders
f magnitude higher than that of 3-HANA. Similarly, ANA, KYNA,
nd XA could not be resolved using ACN.
Because of the different ionizable functional groups of TRP and
ts metabolites, the pH of the mobile phase could influence the
onization state of these compounds. However, because 10 of our
nalytes possess carboxyl group(s), their ionization was  suppressed
t pH < 3, resulting in more hydrophobic species. The majority of
hese metabolites are zwitterionic molecules, and 7 of them have
soelectric points below 6.0, indicating that the carboxyl group is
n the anionic form around pH 6. At higher pH values, more of
hese compounds have additional deprotonized functional groups,
esulting in anionic species. Usually, detection of anionic analytes
ia mass spectrometry in the negative mode results in lower sen-
itivity. Moreover, almost all of our tested columns are reported by
heir respective manufacturers to have poor stability above pH 8.
The same conclusion can be drawn from the calculated logP
nd logD values presented in Table 3 [24]. In reversed-phase HPLC,
etention time is closely related to the hydrophobicity of analytes,
hich can be estimated using logP (octanol/water) values. When an
nalyte is dissociated in the mobile phase, logD (distribution coeffi-
ient, which reflects the contribution of all ionic species to the total
ydrophobicity of an analyte) is often used instead of logP. Increas-
ng pH resulted in lower logD values for almost all tested analytes,
hich again resulted in lower retention time.
Based on the results of column- and organic modifier-scouting
xperiments and the theoretical consideration of the pH of the
obile phase, separation of TRP and its metabolites was performed
n a Kinetex PFP column under acidic conditions using 0.1 % (v/v)
queous FA (pH 2.7) and MeOH as an organic modifier.
Derivatization of the carboxyl group(s) of TRP and 9 of its
etabolites via esterification with four carbon atoms containing
-butanol increased the hydrophobicity of analytes, resulting in
igher retention on reversed-phase chromatographic columns. The
eak shape of the most polar compounds 3-HK, PICA, and QUIN
as optimal after butylation (Fig. 3), and their retention increased
ignificantly. QUIN has two carboxyl groups, and their esterifica-
ion made QUIN the most hydrophobic TRP metabolite. Using a
eneric gradient (see Section 2.5.1), the least retentive esterifiedceutical and Biomedical Analysis 185 (2020) 113246
3-HK eluted immediately before the most retentive nonesterified
metabolite MELA. Esterified 5-HIAA and KYN coeluted, whereas 5
butylated metabolites (TRP, KYNA, 3-HANA, XA, and ANA) grouped
between esterified PICA and QUIN without disturbing the determi-
nation of other analytes.
Considering the chromatographic behavior of esterified and
nonesterified TRP and its metabolites, 7 compounds were selected
for their quantitative estimation in the nonderivatized forms,
whereas 3 metabolites were quantitatively estimated in their buty-
lated forms. SERO and MELA were also analyzed (nonesterifiable),
but their in vivo concentrations proved to be lower than their LOD
in the case of CSF samples. However, SERO could be quantified in
serum samples.
Apart from the type and physical characteristics of the sta-
tionary phase, nature of organic modifier, and composition and
pH of the mobile phase, other chromatographic parameters (e.g.,
length and profile of the gradient, T, ionic strength of the
mobile phase, initial and final organic concentrations of eluents,
and column dimensions) can also influence analyte separation.
Improving the analytical performance testing of these parame-
ters would be tedious and time-consuming, but not cost-effective
or “green.” However, computer-assisted HPLC method devel-
opment/optimization software can help define the appropriate
conditions for robust, precise, and reproducible analysis and can
simultaneously save resources. DryLab®4 is one such software
that helps the chromatographer develop better and more reliable
HPLC/UHPLC methods in a shorter time. This can be achieved by
in silico modeling of retention and resolution based on a limited
number (2–12) of initial experiments [13].
To optimize separation of TRP and its 11 metabolites on a Kine-
tex PFP column using MeOH as an organic modifier, we  performed
four initial linear gradient chromatographic runs to test the effects
of gradient steepness/tG (tG1 = 5 and tG2 = 15 min) and T (T1 = 25 ◦C
and T2 = 50 ◦C) on retention time and resolution. Based on these
chromatograms, the software simulated chromatograms and cre-
ated a 2D color-coded resolution map, plotting critical resolution
as a function of tG and T. Red regions on this plot represent the
optimal chromatographic conditions with a resolution of >1.3. We
selected a working point (tG1 = 5 min, T = 25 ◦C), and using the gradi-
ent editor, we simulated the resolution of the two most problematic
analyte pairs: SERO–KYN and 3-HK–XA (Fig. 5). The best separation
was achieved using a gradient with four linear segments: 0–1 min,
10 %–30 % B; 1–3 min, 30 %–50 % B; 3–3.5 min, 50 %–90 % B; and
3.5–5 min, 90 % B (Fig. 6). Retention time prediction was experi-
mentally verified using the selected parameters. The experimental
(texp) and simulated (tsim) retention times for each analyte, together
with their ratio (r = texp/tsim), are summarized in Table 2. All ratios
ranged from 0.99 to 1.02, indicating an excellent match between
the simulated and actual separations.
DryLab®4 combines over 30 years of HPLC expertise with
the latest software technologies and enables chromatographers
involved in pharmaceutical and chemical industries, environmen-
tal protection, and research industries to easily create fast, robust,
high-quality methods [21]. To the best of our knowledge, this is the
first report on the use of DryLab®4 to optimize LC/MS analysis of
endogenous multianalyte-containing biological samples [25].
3.3. Method validation
3.3.1. Linearity, LOD, and LOQ
The LOD, LOQ, retention time, and linearity of the calibration
curves with r2 values are shown in Supplementary Table 1 for CSF
and Supplementary Table 2 for serum. For all analytes, r2 exceeded
0.99. LOD was less than 7.80 nM,  and in most cases, LOQ was lower
than 8.26 nM for all metabolites, except in SERO and QUIN (23.65
and 20.59 nM,  respectively).
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Fig. 5. DryLab®4 resolution map  with working point (tG = 5 min, T = 25 ◦C).
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.3.2. Precision and accuracy
The intraday and interday precisions (RSD) of the method for
he two matrices were obtained by analyzing five replicates of the
hree QC levels on 3 consecutive days (Supplementary Tables 3–6).
ccording to the results, the developed method was  found to have
 reliable precision.
The accuracy ranged from 86.7-112.0 % of intraday and interday
easurements (Supplementary Tables 3 and 4) in aCSF and from
9.1-107.7 % in the “blank” serum (Supplementary Tables 5 and 6),
hich are in line with recommended data [17,18].
.3.3. Recovery
To measure analyte concentrations, a simple protein precipita-
ion method was selected instead of liquid–liquid or solid-phase
xtraction. In general, protein precipitation is easier, more rapid,
nd reasonable than the abovementioned methods. The process
rst was conducted using ACN and MeOH for aCSF and with sup-
lementation with acetone–MeOH (3:7, v/v) and acetone–MeOH
1:1, v/v) for the “blank” serum. Finally, for protein precipi-
ation, ACN was used for aCSF and acetone–MeOH (1:1, v/v)
or the “blank” serum. Analyte recoveries were determined at
hree different concentrations to prove that the recovery of eachynurenine (2), 3-hydroxyanthranilic acid (3), tryptophan (4), 5-hydroxyindoleacetic
enine (9*), melatonin (10), picolinic acid (11*), quinolinic acid (12*). *, indicates
analyte was concentration independent, reproducible, and consis-
tent.
Analyte recoveries ranged from 93.8-105.3 % for aCSF (Supple-
mentary Table 7) and from 84.7-109.4 % for the “blank” serum
(Supplementary Table 8). Our values are within the range recom-
mended by the ICH and FDA guidelines [17,18].
3.4. TRP metabolite profile changes in multiple sclerosis
In most cases, the quantitative estimation of many analytes
with different polarities is challenging. Hence, derivatization is
commonly used to improve the selectivity and sensitivity of the
method because it changes the chemical properties of compounds
and increases the mass of analytes, which provide an excellent
strategy for avoiding the interference of matrix components [26].
Therefore, to achieve successful simultaneous quantitation of the
12 analytes, a derivatization step was included to improve the peak
shape and retention of 3-HK, PICA, and QUIN. Although the concen-
trations of both SERO and MELA were below their LOD  in CSF and
that of MELA was  also below its LOD in serum, the method was
validated according to the ICH and FDA guidelines [17,18]. Appli-
cability of the method was proven by quantifying the metabolites of
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Fig. 7. Box plots of significant changes between the control and multiple sclerosis groups in cerebrospinal fluid, in the concentrations of kynurenic acid (KYNA), 3-
hydroxykynurenine (3-HK), picolinic acid (PICA), quinolinic acid (QUIN), KYNA/l-kynurenine (KYN), QUIN/KYNA, and PICA/QUIN. Significance was evaluated using an
independent samples t-test or a two-sample Wilcoxon test after the F-test: * p < 0.05; ** p < 0.01; *** p < 0.001.
Table 4
Concentrations of TRP and its metabolites in human cerebrospinal fluid and serum in the control and multiple sclerosis groups.
CSF Serum
Analyte Control group Multiple sclerosis group p-value Control group Multiple sclerosis group p-value
Concentration (nM) Concentration (nM)
SERO  < LOD < LOD – 919.9 ± 451.1 725.9 ± 365.4 0.1761
KYN  49.3 ± 16.6 60.4 ± 21.2 0.1691a 2 397 ± 664.4 2 365 ± 714.9 0.8949
3-HANA 0.7 ± 0.7 1.1 ± 0.8 0.1533a 58.0 ± 20.6 55.3 ± 16.8 0.6853
TRP  1 847 ± 305.6 1 781 ± 367.3 0.9277a 52 043 ± 11 057 50 948 ± 9 325 0.4089
5-HIAA 101.0 ± 36.7 85.8 ± 31.4 0.3487 66.0 ± 21.3 50.7 ± 11.3 0.0248
ANA  7.0 ± 3.9 6.3 ± 3.0 0.7957a 16.2 ± 6.3 15.9 ± 5.0 0.9047
KYNA  0.9 ± 0.6 0.5 ± 0.2 0.0469 32.2 ± 10.4 27.2 ± 9.5 0.1692
XA  0.037 ± 0.034 0.053 ± 0.062 0.8534a 13.7 ± 9.0 10.6 ± 5.0 0.5981a
3-HK 4.7 ± 2.8 6.4 ± 2.6 0.0346a 92.0 ± 46.3 89.8 ± 27.9 0.8724
MELA  < LOD < LOD – < LOD < LOD –
PICA  13.4 ± 4.6 10.0 ± 3.4 0.0224 35.4 ± 8.4 31.6 ± 9.2 0.2586
QUIN  16.4 ± 2.8 24.7 ± 5.1 0.0001 100.5 ± 45.9 158.0 ± 73.5 0.0302
QUIN/KYNA 36.2 ± 37.1 73.2 ± 57.8 0.0015a 3.7 ± 2.0 6.5 ± 2.9 0.0183
KYN/TRP (×103) 28.2 ± 11.1 35.1 ± 14.5 0.1575 48.2 ± 15.8 46.8 ± 13.5 0.9855a
PICA/QUIN 0.8 ± 0.4 0.4 ± 0.2 0.0065 0.4 ± 0.3 0.2 ± 0.2 0.0476a
KYNA/KYN (×103) 18.5 ± 12.3 8.9 ± 5.0 0.0041a 14.2 ± 5.6 11.5 ± 3.3 0.0832a
CSF, cerebrospinal fluid; LOD, limit of detection; SERO, serotonin; KYN, l-kynurenine; 3-HANA, 3-hydroxyanthranilic acid; TRP, tryptophan; 5-HIAA, 5-hydroxyindoleacetic
acid; ANA, anthranilic acid; KYNA, kynurenic acid; XA, xanthurenic acid; 3-HK, 3-hydroxykynurenine; MELA, melatonin; PICA, picolinic acid; QUIN, quinolinic acid.
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ignificant p-values are highlighted in bold. Data are presented as the mean ± SD (co
amples  t-test and two-sample Wilcoxon test.
a Two-sample Wilcoxon test.
nterest from both human CSF and serum in a short study, in which
etabolite concentrations were compared between the multiple
clerosis and control groups.
Investigation of the molecular background of neurodegenera-
ive diseases such as multiple sclerosis requires intensive research,
nd some analytes derived from TRP have been studied compre-
ensively [1,2,5,8]. The need to measure all important metabolites
n a single run is necessary considering the efficiency, financial, and
ime-saving aspects of a method, whereas robustness ensures the
pplicability of the same method on different biological matrices, n = 14; multiple sclerosis, n = 20). p-values were determined using an independent-
which is crucial for better comprehension of the actual pathome-
chanisms of diseases.
In a recent study [8] of TRP metabolites, changes in KYNA,
PICA, QUIN, and 3-HK concentrations were compared between
patients with multiple sclerosis and controls. Our findings are in
line with literature data, and QUIN-induced excitotoxic effects can
be counterbalanced by KYNA. In the context of multiple sclero-
sis, QUIN concentration increased dramatically in both CSF and
serum, whereas KYNA concentration slightly decreased (Table 4
and Figs. 7 and 8), resulting in a significantly higher QUIN/KYNA
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ig. 8. Box plots of significant changes between the control and multiple sclerosis
UIN/KYNA, and PICA/QUIN. Significance was evaluated using an independent samp
atio in the multiple sclerosis group than in the control group. The
UIN/KYNA ratio reflects excitotoxicity because excitotoxicity is
ncreasingly favored as the ratio increases. The hypothesis that exci-
otoxic TRP metabolites can cause neurodegeneration in multiple
clerosis is supported by these data.
The KYNA/KYN ratio (a potential surrogate marker of KAT activ-
ty) decreased in the multiple sclerosis group compared with in the
ontrol group. This originated from decreased metabolism of the
europrotective branch of KP, a phenomenon described in other
isorders [27].
In addition, the PICA/QUIN ratio, which increased in the multi-
le sclerosis group, may  be a result of the ability of neuroprotective
ICA to antagonize QUIN neurotoxicity [28] or may  be representa-
ive of the inflammatory processes in multiple sclerosis.
In CSF samples, the measured 3-HK concentration significantly
ncreased, which is expected because this neurotoxic metabolite is
nown to potentiate QUIN-induced excitotoxicity [8]. Moreover,
UIN is involved in the phosphorylation of neurofilaments, the
tructural components of axons [29]. The increased concentration
f neurofilaments in CSF and serum of patients with multiple scle-
osis reflects the extent of neuroaxonal damage, as described in a
revious study [30].
. Conclusion
We  validated a UHPLC–MS/MS method for the simultaneous
uantitative estimation of TRP and its 11 most important metabo-
ites derived via both KP and SERO pathways (SERO, KYN, 3-HANA,
-HIAA, ANA, KYNA, 3-HK, XA, MELA, PICA, and QUIN). The val-dated chromatographic method is accurate and applicable to
uman CSF and serum. Although 3 metabolites (3-HK, PICA, and
UIN) were analyzed in derivatized forms, they were assessed
ogether with 9 underivatized metabolites in a single run. Theps in serum, in the concentrations of 5-hydroxyindoleacetic acid (5-HIAA), QUIN,
st or a two-sample Wilcoxon test after the F-test: * p < 0.05; ** p < 0.01; *** p < 0.001.
chromatographic method was in silico optimized using DryLab®4.
Selectivity, linearity, LOD, LOQ, precision, accuracy, and recovery
values upon validation were within the acceptable ranges recom-
mended by the ICH and FDA guidelines [17,18]. The applicability
of the chromatographic method was proved by comparing the
described concentrations obtained using biological matrices with
literature data.
This study provides a reference for the clinical and scientific
research of multiple sclerosis. Our results suggest that ratios of dif-
ferent TRP metabolites could be putative biomarkers of this disease.
To the best of our knowledge, this is the first study to quantitatively
estimate derivatized 3-HK, PICA, and QUIN simultaneously with 9
other TRP metabolites in human serum and CSF.
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